Who is sponsoring NCT02899169?

NCT02899169 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT02899169?

Interventions in NCT02899169: Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide, Hydroxyurea.

What condition does NCT02899169 study?

NCT02899169 studies Acute Promyelocytic Leukemia.

Is NCT02899169 still recruiting?

NCT02899169 is currently status unknown. Last updated 8 September 2021.

Last reviewed 2021-09-08 · How we verify

NCT02899169: APL16

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Status unknown Phase 3 Last updated 8 September 2021

What this trial tests

Phase 3 trial testing Realgar-Indigo naturalis formula in Acute Promyelocytic Leukemia in 110 participants. Status unknown.

Timeline

1 September 2016

Primary endpoint
1 September 2022

1 November 2022

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	1 September 2016
Primary completion	1 September 2022
Estimated completion	1 November 2022
Sites	1 location across China

Drugs / interventions tested

Realgar-Indigo naturalis formula
all-trans retinoic acid
Arsenic trioxide (ARSENIC TRIOXIDE) — full drug profile →
Hydroxyurea — full drug profile →

Conditions studied

Acute Promyelocytic Leukemia — all drugs for Acute Promyelocytic Leukemia →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 14 to 70, any sex, with Acute Promyelocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.
Ferreira R, Napoli J, Enver T, Bernardino L, et al · · 2020 · cited 81× · PMID 32848154 · DOI 10.1038/s41467-020-18042-2
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia.
Chen Y, Tong X, Lu R, Zhang Z, et al · · 2024 · cited 16× · PMID 39027338 · DOI 10.3389/fphar.2024.1404092
Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
Zhang X, Liu L, Yao Y, Gong S, et al · · 2020 · cited 4× · PMID 31898521 · DOI 10.1186/s13063-019-3983-2
Arsenic trioxide <i>versus</i> Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial.
Chen S, Qin W, Lu X, Liu L, et al · · 2025 · PMID 39506905 · DOI 10.3324/haematol.2024.285905

Verify or expand the search:

Other trials of Realgar-Indigo naturalis formula

Trials testing the same drug.

NCT05297123 — Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid · Phase 1 · unknown

Other recruiting trials for Acute Promyelocytic Leukemia

Currently open trials in the same condition.

NCT05832320 — Optimum Induction Therapy of Low-risk APL · NA · recruiting
NCT04687176 — Frontline Oral Arsenic Trioxide for APL · Phase 2 · recruiting
NCT04793919 — Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia · Phase 2 · recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02899169 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 8 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02899169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing